Klin Onkol 2004; 17(1): 13-17.
Summary:
Backgrounds: In the last few years, a number of preliminary reports have been published on 99mTc-MIBI as a potential tracer in patients with multiple myeloma.
Design and Subjects: Aims of our study was to evaluate a role of 99mTc-MIBI scintigraphy in the detection of myeloma bone disease and myeloma lesions in soft tissues in multiple myeloma and monoclonal gammopathy of unknown significance, in assessing myeloma activity, and to evaluate the relationship of different patterns of 99mTc-MIBI uptake with clinical status and stage of disease in representative group of patients. 102 consecutive patients with multiple myeloma and 32 patients with monoclonal gammopathy of unknown significance were enrolled in the study.
Methods and results: Anterior and posterior whole-body scans were obtained 10 min after administration of 800 MBq 99mTc-MIBI. Using semiquantitative uptake score the radiotracer uptake was graded according to extension and intensity (summed score). Scintigraphic findings were correlated with clinical and laboratory data. 83 patients with multiple myeloma had active disease and 19 were in remission. The uptake score correlated significantly with clinical status of the disease and markers of disease activity. Overall sensitivity and specificity of 99mTc-MIBI scintigraphy in detecting myeloma bone disease and in assessing myeloma activity were 93% and 79%, respectively. Conclusions: Whole body scanning with 99mTc-MIBI provides a simple and sensitive index of biological activity of disease. A negative scan clearly indicates remission and the uptake score correlates with markers of activity of the disease.
